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Circumferential Pulmonary Vein
Isolation With the Cryoballoon Technique
Results From a Prospective 3-Center Study
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Objectives The purpose of this study was to investigate the efficacy safety of the novel cryoballoon device (Arctic Front,
Cryocath, Quebec, Canada).
Background Antral pulmonary vein (PV) ablation with radiofrequency energy is widely used as a strategy for catheter ablation
of paroxysmal atrial fibrillation (PAF). A novel double lumen cryoballoon catheter was designed for circumferen-
tial pulmonary vein isolation (PVI) with the cryoablation technique.
Methods We consecutively enrolled 346 patients with symptomatic, drug refractory paroxysmal (n  293) or persistent
(n  53) atrial fibrillation (AF). In all patients, PVI of all targeted PVs was the therapeutic aim. The primary end points
of this nonrandomized study were: 1) acute isolation rate of targeted PV; and 2) first electrocardiogram-documented
recurrence of AF. The secondary end point was occurrence of PV stenosis or atrio-esophageal fistula.
Results The 1,360 of 1,403 PVs (97%) were targeted with balloons or balloons in combination with the use of Freezor
Max (Cryocath). We found that ablation with the cryoballoon resulted in maintenance of sinus rhythm in 74% of
patients with PAF and 42% of patients with persistent AF. No PV narrowing occurred. The most frequent compli-
cation was right phrenic nerve palsy observed during cryoballoon ablation at the right superior PV.
Conclusions Pulmonary vein isolation with a new cryoballoon technique is feasible. Sinus rhythm can be maintained in the
majority of patients with PAF by circumferential PVI using a cryoballoon ablation system. Cryoablation was less
effective in patients with persistent AF than in patients with PAF. (J Am Coll Cardiol 2008;52:273–8) © 2008
by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.04.021i
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Aiven limited success rates of drug therapy for atrial
brillation (AF), interventional treatment options have been
eveloped during the last decade (1). Catheter ablation of
F has been established as an important therapeutic strat-
gy. It is recommended as second-line therapy in patients
ith symptomatic AF (2).
rom the *Department of Cardiology, Kerckhoff Heart Center, Bad Nauheim,
ermany; †Department of Cardiology, Heart and Diabetes Center North Rhine-
estphalia, Ruhr University Bochum, Bad Oeynhausen, Germany; and the ‡De-
artment of Cardiology, Center of Cardiovascular Medicine, Bad Neustadt/Saale,
ermany. Dr. Vogt has received speakers’ honoraria and honoraria for advisory board
eetings from Cryocath; Dr. Schumacher has been on the Speakers’ Bureau of
ryocath; Dr. Kuniss has received speakers’ honoraria from Cryocath; Dr. Heintze
as received honoraria for cryo training from Cryocath; and Dr. Pitschner has received
onoraria for advisory board meetings from Cryocath.e
Manuscript received January 15, 2008; revised manuscript received March 12,
008, accepted April 3, 2008.The cornerstone of catheter ablation for AF is electrical
solation of the pulmonary veins (PVs). New technical
evelopments have been used in order to simplify pulmo-
ary vein isolation (PVI) and to reduce the procedure time
y using an anatomically based ablation approach. Catheters
esigned as balloons might be more effective and safe to use
or circumferential ablation (3–5). The purpose of the
resent study was to investigate the effectiveness and the
afety of a novel cryoballoon device (Arctic Front, Cryocath,
uebec, Canada).
ethods
atients. The study enrolled 346 consecutive patients with
ymptomatic and drug refractory paroxysmal or persistent
F. In all patients, AF was documented at least on separatelectrocardiograms (ECGs) within the last 3 months
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Circumferential PVI With the Cryoballoon Technique July 22, 2008:273–8before ablation. Exclusion cri-
teria were defined as advanced
structural heart disease includ-
ing moderate-to-severe valvular
stenosis or insufficiency, previous
myocardial infarction, congenital
heart disease, left ventricular
ejection fraction 45%, coronary
artery bypass graft surgery within
the last 3 months, chronic obstruc-
tive pulmonary disease treated
with beta-sympathomimetic drugs,
severe respiratory insufficiency,
known bleeding diathesis or intol-
rance of heparin or oral anticoagulation, attempted AF
blation in the past, left atrial (LA) thrombus, pregnancy, and
evere comorbidity.
re-ablation. Medical history was obtained during the
linic visit and a review of the medical records including
CGs and Holter ECG recordings showing episodes of
F. The risk of ablation was discussed in detail, and all
atients gave written informed consent before the proce-
ure. The study was approved by the local institutional
thics committee. Three days before intervention, coumadin
as stopped and replaced by subcutaneous low-molecular-
eight heparin. All antiarrhythmic drugs including amio-
arone were discontinued at least 3 days before ablation.
eta-blockers were allowed according to the protocol. All
atients underwent transthoracic echocardiography to de-
ermine LA diameter. To assess PV size and geometry,
agnetic resonance imaging (MRI) or computer tomogra-
hy images were obtained before intervention.
nterventions. Procedures were performed under con-
cious sedation and analgesia with appropriate doses of
idazolam and dipidolor. During the catheter procedure,
n infusion of heparin was maintained to achieve an
ctivated clotting time 300 s. Measurements were per-
ormed every 30 min routinely.
A diagnostic quadripolar catheter (Biosense Webster
nc., Diamond Bar, California) was positioned in the
oronary sinus for stimulation of the LA. The LA was
ccessed via the transseptal route from the right femoral vein
ith a steerable 12-F sheath (FlexCath, Cryocath) to guide
double walled cryoballoon (Arctic Front, Cryocath) over
he wire (Emerald guidewire 0.32-F, Cordis, Johnson &
ohnson, Diamond Bar, California). A second transseptally
ntroduced 8-F sheath (Fast Cath, SJM, Minnetonka,
innesota) was used for placement of a multipolar Lasso
atheter (Biosense Webster) into the LA to map signals
efore and after ablation at the ostial sides of PVs. After
ngiography in the left anterior oblique 60° and right
nterior oblique 30° or anterior-posterior projections, each
V was mapped. With different sizes of Lasso catheters
Biosense Webster), we mapped inside the PVs (15-mm
asso catheter) and outside at the level of PV antrum (20-
Abbreviations
and Acronyms
AF  atrial fibrillation
LA  left atrium/atrial
MRI  magnetic resonance
imaging
PAF  paroxysmal atrial
fibrillation
PNP  phrenic nerve palsy
PV  pulmonary vein
PVI  pulmonary vein
isolationo 25-mm Lasso catheters). In 34 cases we assessed imme- miate success of ablation with the NavX system (Endocardial
olutions, St. Jude Medical, Inc., St. Paul, Minnesota).
omplete isolation was verified as a reduction of all signals
0.2 mV. Exit block from the vein was confirmed by pacing
t the location of bipolar signals within the PV ostium in all
atients. During sinus rhythm, cryoballoon ablation was
erformed after mapping the areas of interest distal to the
ntrum. During AF, the transition zone was defined pri-
arily by anatomical orientation, since the cryoballoon itself
oes not have any electrodes for recording of local electrical
ignals.
There are currently 2 sizes of balloon catheters available
23 or 28 mm). Before the ablation procedure, the diameters
f the PVs were determined by computed tomography/MRI
can. The balloon size was selected accordingly. With the
eflated balloon catheter inside the sheath, a guidewire was
laced in one of the PV branches. The balloon was then
dvanced towards the PV ostium and inflated. The degree
f balloon occlusion obtained by injection of 50% diluted
ontrast medium into the PV was judged using a semiquan-
itative grading: grade 4  excellent (full retention of
ontrast medium without visible outflow) to grade 1  very
oor (immediate rapid outflow from the PV). We aimed for
t least 1 cryoballoon ablation with occlusion of grade 4 on
very targeted PV. Additional delivery of cryoenergy was
pplied after the guidewire was placed in different branches
f the PV with early branching, which usually allowed for
etter contact of the balloon at different sites of the PV
ntrum.
Based on the animal data (6), we chose an application
ime of 240 to 360 s per freeze. Balloon temperature was
easured at the proximal end of the balloon where the
aporized N2O was sucked back into the console.
During cryoablation of the antrum of the right-sided
Vs, unaffected phrenic movement was monitored by either
ontinuous phrenic nerve stimulation via a right atrial
timulation catheter or by continuous monitoring of spon-
aneous breathing. In all patients, PVI of all targeted PVs
as the therapeutic aim with the primary use of a cryobal-
oon only. An observation period after isolation to check for
ecurrence of conduction was 20 min. If a PV could not be
eached with a cryoballoon or no isolation could be achieved
fter 5 applications with any balloon, an 8-mm tip cryoab-
ation catheter (Freezor Max, Cryocath) was used to finish
VI with signal control at the Lasso catheter.
ost-ablation management. Intravenous heparin was con-
inued to achieve a partial thromboplastin time of 50 to 70 s.
etween post-interventional days 2 and 5, a 24- to 48-h
olter ECG was obtained in every patient. Before hospital
ischarge, all patients underwent transthoracic echocardi-
graphy to exclude pericardial effusion and chest X-ray to
ocument adequate phrenic movement.
Oral anticoagulation with coumadin was started 1 day
fter PVI, targeting an international normalized ratio of 2.0
o 3.0 for at least 3 months. During a blanking period of 3
onths, antiarrhythmic treatment was allowed even in
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July 22, 2008:273–8 Circumferential PVI With the Cryoballoon Techniquesymptomatic patients to facilitate maintenance of sinus
hythm. Antiarrhythmic drugs were stopped after 3 months
n the majority of patients. Antiarrhythmic drug therapy
as continued only in patients with ongoing highly symp-
omatic episodes of AF beyond 3 months after intervention.
ollow-up. After discharge from the hospital, patients
ere scheduled for quarterly follow-up visits. Late
ollow-up (1 year post-intervention) was performed once
year. Seven-day Holter ECG recordings were obtained at
ach follow-up visit. Patients without documented AF
uring follow-up who received antiarrhythmic drug therapy
ith amiodarone or class I antiarrhythmic agents at the
iscretion of their physician (n 5) were excluded from the
nalysis of the second primary end point. The main reason
or this intermittent drug therapy was premature beats.
uring a follow up of 3 to 12 months, at least 1 MRI/
omputed tomography scan was performed to assess PV
iameters and to exclude PV stenosis.
tudy end points. The primary end points of this nonran-
omized study were: 1) acute isolation rate of targeted PV;
nd 2) first ECG documented recurrence of AF after a
lanking period of 3 months in the absence of any antiar-
hythmic drug therapy. The secondary end point was the
ccurrence of PV stenosis or atrio-esophageal fistula and
eri-interventional safety.
tatistical analysis. For statistical analysis, Kaplan-Meier
nivariate analysis and a multivariate Cox regression model
ere used to estimate AF-free survival. All continuous
ariables were tested on normality using the Kolmogorov-
mirnov test. Normal distributed variables were analyzed
sing a paired and unpaired t test (2 groups analysis) and
nalysis of variance (N groups analysis). In the case of
onnormal distribution, continuous variables were analyzed
sing the Wilcoxon matched pairs test/Mann-Whitney U
est (2 groups analysis) and Kruskal-Wallis H test/Friedman
est (N groups analysis). Continuous data were described in
edian, lowest (Q25), and highest (Q75) quartiles.
esults
atients. In total, 346 consecutive patients were treated
ith circumferential antral PVI using a new cryoballoon
atheter. Clinical characteristics are given in Table 1.
rocedural characteristics. The median total procedure
ime was 170 (interquartile range 25/75  140 to 195) min.
he median fluoroscopy time was 40 (30 to 57) min. Total
ryoablation time was 46 (26 to 60) min/patient. Time of
pplications per freeze was 300 (range 28 to 480) s with a
edian number of applications 11 (9 to 13). The median
umber of cryoballoon applications per PV was 2.8 (2.3 to
.4). Early discontinuation of an application was mainly due
o right phrenic nerve palsy (PNP) detected by deep
reathing or stimulation of the right phrenic nerve during
blation of the right superior PV.
A total of 1,360 of 1,403 PVs (97%) could be isolated
ith 1 or 2 balloons, or balloons in combination with the fse of Freezor Max (Cryocath) in 58 patients. Fourteen
atients had a common ostium of the left-sided PV, and a
ight-sided accessory PV was observed in 5 patients. In 109
Vs, the use of Freezor Max was required with a distribu-
ion as follows: left superior PV, n  24; left inferior PV,
 21; right superior PV, n  28; right inferior PV, n  36.
he median number of cryo applications with the Freezor
ax was 3 (2 to 5) per PV. In 116 patients, small balloons
ere initially selected. In 230 patients, the procedure was
tarted with a 28-mm balloon. We observed no significant
ifferences in the number of cryoballoon applications, total
ryo time per PV, procedure time, the incidence of acute PV
solation between a 23-mm balloon and a 28-mm balloon,
nd long-term success. The fluoroscopy time was signifi-
antly higher with 28-mm balloons versus 23-mm balloons
median fluoroscopy time 46 min vs. 33 min).
At least 1 cryoenergy application with grade 4 occlusion
n every targeted PV could be achieved in 90% of the PVs.
hirty-three patients (9.5%) needed more than 1 size of
ryoablation balloon for PVI. The initial degree of vein
cclusion in these cases was mostly 3 and sometimes grade
, but none of these cases had an occlusion grade of 4. In 6
f these 33 patients, the combination 23-mm balloon and
8-mm balloon and cryotip catheter were used for PVI. In
he case of an ECG document with typical flutter, we
dditionally performed a right atrial isthmus block (n  26
atients).
ollow-up results. Median follow-up was 12 (7 to 16)
onths; in 264 patients follow-up was 6 months, and in
33 patients follow-up was more than 12 months. Of 346
atients (Table 1), 55 did not exceed the blanking period
nd were only available for analysis of acute results. In 4
atients, the Holter times were too short or it was not
ossible to analyze because of artefacts in the Holter. A
urther 9 patients were lost in follow-up without informa-
ion where they could be reached. Fourteen patients refused
aseline Characteristics of Patientsith Paroxysmal and Persis AF
Table 1 Baseline Characteristics of PatientsWith Paroxysmal and Persistent AF
Paroxysmal AF
(n  293)
Persistent AF
(n  53) p Value
Gender, male/female 173/120 41/12 NS
Age, yrs 59 (51–65) 59 (52–66) NS
Duration of AF, yrs 6.5 (5.3–7.5) 7.7 (5.6–8.7) NS
Number of unsuccessful
antiarrhythmic drug therapies
n 3 100 21 NS
n 3 193 32 NS
Left atrial diameter
Short axis, mm 40 (37–42) 42 (40–44) 0.001
Long axis, mm 52 (48–56) 57 (52–59) 0.001
Left ventricular ejection fraction, % 60 (60–60) 60 (55–60) NS
Hypertension 129 25 NS
Other mild heart disease 42 16 0.01
umbers are counts and the continuous data were described in median, lowest (interquartile range
5), and highest (interquartile range 175) quartiles. AF  atrial fibrillation.urther follow-up visits. None of the patients that we could
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Circumferential PVI With the Cryoballoon Technique July 22, 2008:273–8each by telephone contact underwent a further radiofre-
uency ablation due to recurrence. The 14 patients who
efused further follow-up visits were free of symptomatic
rrhythmias evaluated by telephone interview. Repeat abla-
ion was performed in 35 patients. These patients were
ounted as “failures” because they had reached the primary
nd point of recurrence of AF.
Freedom from documented paroxysmal and persistent
F-free survival is given in Figure 1. We found that
ircumferential PVI with the cryoballoon technique resulted
n maintenance of sinus rhythm without the use of antiar-
hythmic drug therapy in 159 (74%) patients with paroxys-
al atrial fibrillation (PAF). In total, in 41 patients antiar-
hythmic drug therapy with amiodarone or class I agents
ere not discontinued at the time of 3 months follow-up.
aintenance of sinus rhythm without the need for antiar-
hythmic drug therapy was observed in only 13 of 31
atients (42%) with persistent AF.
The multivariate Cox regression model revealed that
ersistent AF and long axis of the LA (evaluated by
chocardiography)60 mm were independent predictors of
ocumented recurrence after adjustment for other clinical
ariables including gender, age, hypertension, mild heart
isease, left ventricular ejection fraction, and LA diameter.
s PV diameters may change on different occasions, a
eduction of 30% was set as a potential procedure-related
arrowing, which was not observed in any patient. In 310
atients, MRI was performed to measure PV diameters
efore ablation. Data on 1,222 PVs were available. Mea-
urements were done as described elsewhere (7). The
edian (interquartile range 25/interquartile range 75) di-
meters of left superior PV, left inferior PV, right superior
V, and right inferior PV were 18 (16 to 21), 17 (16 to 18),
0 (17 to 21.5), and 18 (16 to 20) mm in the large axis of
Figure 1 PAF Versus Persistent AF
Kaplan-Meier curves of electrocardiogram-documented paroxysmal (PAF) (con-
tinuous line) and persistent (Pers) (dashed line) atrial fibrillation (AF)–free sur-
vival after pulmonary vein isolation with a blanking period of 3 months.oostly oval-shaped PV. During follow-up, PV measure-
ents of 239 patients were available. No stenosis or a
iameter reduction 30% was observed.
omplications. Early periprocedural complications (2
ericardial tamponades) were observed and treated with
ericardial drainage; both resolved without the need for
urgery. We observed 5 patients with groin hematoma, no
atients with retroperitoneal bleeding, 2 patients with fem-
ral arterial pseudoaneurysm, and 1 patient with femoral
rteriovenous fistula. All of these cases with vascular com-
lications could be managed conservatively.
In 26 of 346 patients, right PNP was observed during
ryoablation of the right superior PV. In 24 of 26 patients,
NP occurred when using a 23-mm balloon. Only in 2
atients was PNP related to cryoablation with a 28-mm
alloon. Two of the 26 PNP cases resolved during the
rocedure. An early termination of cryoenergy application
uring right phrenic pacing did not prevent the subsequent
ccurrence of PNP. In all patients, full recovery of right
hrenic function was observed during follow-up of less then
year. In 2 patients, transient ST-segment elevation be-
ause of bubbles inside of the sheath occurred in the inferior
eads without hemodynamic compromise. It resolved within
2 min in both patients. We additionally observed 2
atients (0.8%) with LA flutter occurring within 3 months
fter the intervention. These 2 patients were not included in
he subsequent analysis of long-term successful ablation.
oth cases successfully resolved with a further LA ablation
rocedure. We observed no other atrial tachycardia or atrial
utter during follow-up. No patients developed an atrio-
sophageal fistula, stroke, death, or other peri-interventional
omplication.
iscussion
he emerging need for better safety and facilitation of
atheter ablation for AF has recently been emphasized in
ifferent expert consensus statements (Heart Rhythm Soci-
ty/European Heart Rhythm Association/European Car-
iac Arrhythmia Society/American College of Cardiology/
merican Heart Association) (8,9). Novel technologies
ncluding high-intensity focused ultrasound, laser ablation,
nd the cryoablation technique are currently under investi-
ation (3,10–13). We found that circumferential PVI with
he cryoballoon technique resulted in maintenance of sinus
hythm without the use of antiarrhythmic drug therapy in
4% of patients with PAF. In patients with persistent AF,
ryoballoon ablation was less effective.
ain findings in comparison with those of previous
tudies. Our study demonstrates that PVI using the cryo-
alloon technique is effective in PAF independently of the
ntiarrhythmic drug use. We documented that the patients
emained free from AF by means of serial Holter ECG
ecording including the use of a 7-day event recorder
hroughout follow-up. Comparison of these results with
ther published PVI studies using radiofrequency energy
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July 22, 2008:273–8 Circumferential PVI With the Cryoballoon Techniqueight be impeded because of different follow-up consider-
tions and different definitions of the study end points
14–20). We used: 1) serial 7-day Holter ECG monitoring;
) a strong end point (documented AF relapses); 3) the
ingle procedure success rate without creation of additional
inear lesions; and 4) Kaplan-Meier analysis to report
utcome and not freedom from AF on a monthly basis.
omparable radiofrequency ablation studies based on the
patients’ clinical characteristics” demonstrated single pro-
edure efficacy of 42% to 88%. Particularly with regard to
he studies with a better outcome, they mostly used a
ombined ablation strategy with PVI and additional sub-
trate modification (ablation of complex electrograms, mi-
ral isthmus line, posterior LA line) (14,19,20).
The recently published early results after PVI using the
ryoballoon system in 57 patients with PAF by Jordaens
t al. (11) are comparable to our study. This group demon-
trated acute success rates, complications, and outcome from
short-term follow-up of 3 months. They reported success-
ul balloon isolation in 84% (185 of 220) of all treated PVs,
hich could be upgraded by the use of an additional linear
ryocatheter to 99%. In our study, 92.5% (1,298 of 1,403
Vs) could be targeted with a cryoballoon alone, or the
ryoballoons in combination with a cryotip catheter in 97%
1,360 of 1,403) of all targeted PVs. They also found a rare
ccurrence of atrial tachycardias after cryoballoon ablation
1 patient). Comparing the outcome of their short-term
tudy with our results (median 12 months), in both studies
he majority of patients remained free from AF after a single
rocedure. In the study by Jordaens et al. (11), all patients
eceived antiarrhythmic drugs after the procedure. We
ound a success rate of 74% without the use of antiarrhyth-
ic drug therapy and a further 5 patients without docu-
ented AF who received an additional empirical drug
herapy from their treating physician. The main reason for
his intermittent drug therapy was premature beats with
hort symptomatic palpitations. Several studies have dem-
nstrated that complaints of palpitations often result from
trial or ventricular premature beats and are not an accurate
redictor of recurrent AF (21).
In 58 patients, it was impossible to create a complete
solation of all PVs with the cryoballoon alone. In these
ircumstances, we achieve our therapeutic aim with the use
f a large tip catheter to finish PVI. The main reason for
he inability to achieve complete isolation was anatomic
eatures such as oval-shaped PV ostia or inferior veins
nserting onto the LA with a sharp angulation. In our
xperience, the potential learning curve in using this new
echnology is not a sufficient explanation in such situations
ith special anatomic features, and further device configu-
ation would be helpful.
At the beginning of this study, it was unclear if a sole
ntral PVI strategy might be successful for the treatment of
ersistent AF, and so we also included 53 patients with
ersistent AF. The outcome in these patients was poor.e observed significant differences of atrial dimensions petween patients with PAF versus persistent AF in our
tudy (Table 1). We speculate that one reason for poor
utcome in persistent AF might be that the depth of
enetration using the cryoballoon technique is inade-
uate. Possibly, the strategy of atrial PVI or the cryobal-
oon device does not produce sufficient substrate modifi-
ation as required in persistent AF.
omplications. The major complication reported by Jor-
aens et al. (11) was PNP. In their study, all but one of the
NP cases occurred during a cryoablation with a 23-mm
alloon. These results are supported by our findings. We
ound PNP in 24 of 26 patients who had ablation with a
3-mm balloon. Jordaens et al. (11) did not report on the
ndings of PNP in the long-term because only a short-term
ollow-up was presented. We observed the full recovery
rom PNP in our patients between some minutes after
nergy application up to 1 year after the ablation procedure.
Phrenic nerve injury is an important complication of AF
blation (4,22). Phrenic nerve injury has been seen more
requently with the use of balloon ablation catheters irre-
pective of the energy source (3,5) and with ablation in the
ight superior PV. The multicenter study of Sacher et al.
22) reported a complete recovery of phrenic nerve injury in
2 of 18 patients (66%) after 12 months. The latest recovery
as observed after 19 months. However, in 3 patients, PNP
ad not recovered after 96 months. These patients remained
ymptomatic with dyspnea. The most common complica-
ion in our study was transient PNP. This complication
esolved over time in all of our patients. To the best of our
nowledge, no chronic phrenic nerve injury after transcuta-
eous cryoballoon ablation has been reported in other
tudies. This seems to be different with high focus ultra-
ound ablation (4,5,10). Kuck et al. (10) reported that 2 of
5 patients (13.3%) treated with high-intensity focused
ltrasound developed a right-sided PNP that did not resolve
fter 12 months follow-up. Natale et al. (4) reported only
bout a partial return of phrenic nerve function at the
-month follow-up after circumferential ultrasound ablation
or AF.
Pulmonary vein stenosis is a well-recognized complica-
ion of AF ablation using radiofrequency energy. Pulmonary
ein stenosis can be prevented by avoiding radiofrequency
nergy application within a PV. However, the worldwide
urvey of AF ablation reported a 1.3% incidence of persis-
ent PV stenosis. The preferred therapy for severe symp-
omatic PV stenosis is PV angioplasty, as recently recom-
ended (8). In our study, no PV stenosis was observed
espite ablation at the PV. This finding emphasizes that
ryoenergy is safe with respect to PV stenosis in comparison
ith other energy forms.
tudy limitations. The patients treated in this study suf-
ered from paroxysmal or persistent AF. A conclusive
omparison between the cryoballoon technology and radio-
requency ablation strategies requires randomized trials. We
ave no control group of patients in our study. In 41
atients (11.8%), antiarrhythmic drug therapy with amio-
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Circumferential PVI With the Cryoballoon Technique July 22, 2008:273–8arone or class I agents was not discontinued at the time of
-month follow-up. Fifty-five patients (15.9%) were not
ccounted for in the final analysis of follow-up results as
hey did not complete follow-up beyond the blanking
eriod.
Our results might be influenced by a learning curve as
lready discussed by others (11). No patients developed an
trio-esophageal fistula. Since the estimated incidence of
trio-esophageal fistula after radiofrequency ablation of AF
as been reported to be less than 0.25% (1,23,24), the
umber of patients in our study is too small to definitely
xclude this complication that follows cryoballoon ablation
echnology.
onclusions
inus rhythm can be maintained in the majority of patients
ith PAF by means of circumferential PVI using cryobal-
oon ablation. However, this cryoballoon ablation strategy is
ot recommended in patients with persistent AF. Phrenic
erve injury is a potential, but not life-threatening, compli-
ation during the use of this balloon system. No PV stenosis
r atrio-esophageal fistula occurred in our study.
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